Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in J apanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study
Authors:
Open Access
- 8 January 2016
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 18 (3) , 249-257
Abstract
Aims: To examine the efficacy and safety of once‐weekly dulaglutide 0.75 mg monotherapy compared with once‐daily liraglutide 0.9 mg in J apanese patients with type 2 diabetes ( T2D ) for 52 weeks. Methods: We conducted a phase III , randomized, 52‐week (26‐week primary endpoint), active‐ and placebo‐controlled trial comparing 492 J apanese patients (dulaglutide, n = 281; liraglutide, n = 141; and placebo, n = 70). Participants and investigators were blinded to treatment assignment for dulaglutide and placebo but not for liraglutide (open‐label comparator); after 26 weeks, patients randomized to placebo were switched to once‐weekly dulaglutide 0.75 mg (open‐label). The present paper reports results for patients treated with dulaglutide and patients treated with liraglutide for 52 weeks. Results: At week 52, dulaglutide decreased HbA1c significantly from baseline compared with liraglutide [least squares mean difference: −0.20; 95% confidence interval ( CI ) −0.39, −0.01; p = 0.04]. At week 52 (last observation carried forward), dulaglutide significantly decreased pre‐ and post‐dinner blood glucose ( BG ) levels, the mean of seven‐point self‐monitored BG profiles, the mean of all postprandial BG levels and circadian variation compared with liraglutide. Body weight was generally stable in both groups through 52 weeks. The most frequently reported adverse events were nasopharyngitis, constipation, nausea and diarrhoea. Eight dulaglutide‐treated (2.9%) and four liraglutide‐treated (2.9%) patients reported hypoglycaemia, with no event being severe. Conclusions: Monotherapy with once‐weekly dulaglutide 0.75 mg was effective and safe in J apanese patients with T2D , with better glycaemic control compared with once‐daily liraglutide 0.9 mg.Keywords
Funding Information
- Eli Lilly and Company
- Novo Nordisk
- Sanofi
- Boehringer Ingelheim
This publication has 22 references indexed in Scilit:
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 studyThe Lancet Diabetes & Endocrinology, 2014
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyThe Lancet, 2013
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitusNature Reviews Endocrinology, 2012
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)Diabetes Care, 2012
- Clinical Implications of Exenatide as a Twice-Daily or Once-Weekly Therapy for Type 2 DiabetesPostgraduate Medicine, 2011
- Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetesCurrent Medical Research and Opinion, 2010
- Improved glycaemic control with minimal hypoglycaemia and no weight change with the once‐daily human glucagon‐like peptide‐1 analogue liraglutide as add‐on to sulphonylurea in Japanese patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2010
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Defining and Reporting Hypoglycemia in DiabetesDiabetes Care, 2005
- World Medical Association Declaration of HelsinkiJAMA, 1997